Wolverine Asset Management LLC Travere Therapeutics, Inc. Put Options Transaction History

Wolverine Asset Management LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 01, 2024	BUY	$5.26 - $8.28 $6,838 - $10,764	1,300 Added 100.0%	2,600 $21,000
Q1 2024 May 13, 2024	SELL	$7.18 - $9.82 $108,418 - $148,282	-15,100 Reduced 92.07%	1,300 $10,000
Q4 2023 Feb 01, 2024	SELL	$5.44 - $9.5 $4,896 - $8,550	-900 Reduced 5.2%	16,400 $147,000
Q3 2023 Nov 13, 2023	BUY	$7.64 - $17.25 $19,100 - $43,125	2,500 Added 16.89%	17,300 $154,000
Q2 2023 Aug 07, 2023	BUY	$15.3 - $22.61 $71,910 - $106,267	4,700 Added 46.53%	14,800 $227,000
Q1 2023 May 08, 2023	SELL	$17.82 - $22.89 $295,812 - $379,974	-16,600 Reduced 62.17%	10,100 $227,000
Q3 2022 Nov 10, 2022	SELL	$22.91 - $28.63 $311,576 - $389,368	-13,600 Reduced 33.75%	26,700 $657,000
Q2 2022 Aug 03, 2022	BUY	$20.94 - $30.01 $138,204 - $198,066	6,600 Added 19.58%	40,300 $976,000
Q1 2022 May 04, 2022	BUY	$23.61 - $30.6 $795,657 - $1.03 Million	33,700 New	33,700 $868,000

184

89.8M

137K

181K

Ticker TVTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,173,600
Market Cap $898M
Description
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...

Get notified when there are updates to the investment portfolio of Wolverine Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Wolverine Asset Management LLC with notifications on news.